ReviewCurrent atherosclerosis reports2026
Beyond the Coronaries: Utility of Extra-Coronary Calcification for Cardiovascular Risk Assessment in Women.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGlobally, cardiovascular disease (CVD) is the leading cause of mortality in women. Traditional risk calculators underestimate atherosclerotic cardiovascular disease risk (ASCVD), particularly in women classified as low or intermediate risk. While coronary artery calcium scoring improves risk stratification, it remains underutilized in practice. Extra-coronary calcification (ECC), including breast arterial calcification, valvular calcification, and thoracic aortic calcification have emerged as promising adjunctive imaging biomarkers for cardiovascular risk assessment in women. RECENT
findingsThe processes of vascular and valvular calcification are influenced by inflammation, osteogenic signaling pathways, and sex hormones. Unique female factors, such as the menopausal transition, parity, and pregnancy-related complications, further influence calcification. The incidental ECC detection that is possible through screening mammography, echocardiography, and chest computed tomography offers an opportunity for cardiovascular risk identification without additional cost or radiation. Evidence has suggested ECC to be independently associated with coronary artery disease, stroke, heart failure, atrial fibrillation, and cardiovascular mortality. Further, studies have shown links between ECC with higher cardiovascular risk, particularly among women whose risk may be underestimated by traditional tools. In women, ECC may be valuable as a complementary ASCVD risk-enhancing marker, serving to augment and expedite preventive care. Heterogeneity in ECC recognition, a lack of standardized scoring, and limited prospective outcome data have prevented the integration of ECC metrics into cardiovascular guidelines to date. Future efforts should prioritize standardized reporting, artificial intelligence-assisted quantification, and well-designed prospective trials to determine whether ECC-guided prevention might improve cardiovascular outcomes in women.
Indexed as
Identifiers
42189365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.